Engineered CARD11–PIK3R3 T‐cell therapies as weapons of cancer mass destruction

Wanlu Zhang, Min Wu, Yongye HuangMedComm 2024 · DOI

TL;DR

Researchers have engineered T-cells with a naturally occurring gene fusion, CARD11-PIK3R3, to dramatically enhance their anti-tumor activity. This breakthrough promises to overcome limitations in current T-cell therapies, offering a more potent and potentially safer weapon against refractory cancers.

What Problem Does This Paper Address?

Despite the revolutionary impact of immunotherapy, particularly engineered T-cell therapies like CAR-T and TCR-T cells, a significant challenge remains: their efficacy is limited in a large proportion of cancers. Many cancers develop mechanisms to evade immune responses, and existing T-cell therapies often fail to achieve lasting therapeutic effects. Furthermore, current T-cell therapies can sometimes lead to severe side effects, including immune-related adverse events (irAEs), which can necessitate immunosuppressive treatments that may, in turn, impair the effectiveness of other immunotherapies. This paper addresses the critical need for more potent, targeted, and potentially safer engineered T-cell therapies that can overcome tumor resistance and minimize off-target effects.

Methods

The core of this research lies in identifying and engineering specific genetic modifications within T-cells to boost their anti-cancer capabilities. The authors leveraged a T-cell mutation library created from T-cell neoplasms, containing 71 mutations and 45 wild-type variants. This library was screened to identify genetic alterations that enhance T-cell function.

A key technique involved the introduction of a specific gene fusion, CARD11-PIK3R3, into therapeutic T-cells. This fusion is known to enhance the CARD11-BCL10-MALT1 (CBM) complex signaling pathway. The researchers utilized lentiviral constructs to deliver these genetic modifications.

To validate the efficacy of these engineered T-cells, they employed in vivo models, including:

  • CD19+ Nalm6 xenograft leukemia models: This model assesses the effectiveness of CAR-T cells against a specific type of leukemia.
  • Mesothelioma subcutaneous models (M28): This model evaluates T-cell therapy against mesothelioma.
  • B16-F10 melanoma models expressing human CD19 (B16-hCD19+): This model tests the therapy's effectiveness against melanoma.
  • Human gastric carcinoma cells: This model was used to assess TCR T-cell therapy's ability to clear tumor cells.

The study also involved TCR gene knockout to improve the specificity and safety of CAR-T cells.

Datasets

The paper does not explicitly mention the use of large, pre-existing datasets for training or evaluation in the traditional machine learning sense. Instead, the "dataset" can be considered the T-cell mutation library generated by the researchers, which comprised 71 mutations and 45 wild-type variants derived from T-cell neoplasms. This library served as the source for identifying the CARD11-PIK3R3 gene fusion. The validation was performed using established in vivo tumor models in mice.

Key Insights and Ideas

  • Harnessing Natural Mutations for Enhanced Efficacy: The most significant insight is the demonstration that naturally occurring mutations found in T-cell neoplasms can be repurposed to create significantly more potent therapeutic T-cells. This moves beyond solely designing novel constructs to leveraging existing biological adaptations.
  • CARD11-PIK3R3 as a Potent Enhancer: The CARD11-PIK3R3 gene fusion emerges as a critical player, acting as a potent enhancer of T-cell anti-tumor activity by boosting key signaling pathways (CBM complex, AP-1, NF-κB) and increasing IL-2 production.
  • Improved T-cell Fitness and Function: The engineered T-cells exhibit enhanced proliferation, improved memory phenotype, and superior effector function, leading to more robust anti-tumor responses.
  • Reduced Reliance on Pretreatment: The enhanced efficacy of CARD11-PIK3R3 modified T-cells may reduce the need for intensive lymphodepletion pretreatment, a common and sometimes toxic component of current T-cell therapies.
  • Potential for Reduced Side Effects: By enhancing the T-cells' intrinsic killing capacity, this approach could potentially lead to better tumor clearance with fewer off-target effects and a reduced risk of irAEs, although this requires further investigation.
  • Long-Term Safety Demonstrated: Promisingly, long-term studies showed no signs of lymphoma relapse even after high-dose T-cell transplantation, suggesting a favorable safety profile.

Key Results

  • Engineered T-cells with the CARD11-PIK3R3 gene fusion demonstrated significantly elevated anti-tumor activity in multiple immunotherapy-refractory models.
  • The CARD11-PIK3R3 mutation significantly increased activator protein 1 (AP-1) and nuclear factor-κB (NF-κB) signaling in T-cells, leading to enhanced T-cell activation and function.
  • This mutation enhanced the production of interleukin-2 (IL-2), driving T-cell proliferation and immune responses.
  • In the CD19+ Nalm6 xenograft leukemia model, treatment with CARD11-PIK3R3 enhanced CAR-T cells resulted in 100% survival at 33 days, compared to only 24 days median survival with normal CAR-T cells.
  • CARD11-PIK3R3 TCR T-cells effectively cleared human gastric tumor cells and controlled tumor cell invasion and metastasis in mice.
  • The engineered T-cells showed no signs of lymphoma relapse up to 418 days post-overdose of T-cell transplantation in long-term studies.

Limitations and Future Work

  • Further Exploration of Mutations: While CARD11-PIK3R3 is a promising candidate, the authors suggest the need to further explore the potential influence and impact of other naturally occurring mutations on T-cell phenotype.
  • Clinical Application Feasibility: The paper highlights the need to develop a "relatively safe and feasible plan for clinical application" of these engineered T-cell therapies. This implies that while the preclinical data is strong, translation to human trials requires careful planning and validation.
  • Understanding Antigen-Dependent Effects: The study notes that CARD11-PIK3R3 holds antigen-dependent phenotypic effects. A deeper understanding of how these effects manifest across different tumor types and antigens would be beneficial.
  • Minimizing irAEs: While the approach shows promise for reducing side effects, further research is needed to definitively confirm its impact on minimizing immune-related adverse events in a clinical setting.

Summary updated

Abstract

Garcia et al. discover a novel immunotherapy approach by engineering naturally occurring mutations in therapeutic T cells to strongly elevate anti-tumor activity. The authors identify a gene fusion, CARD11-PIK3R3, to increase activator protein 1 and nuclear factor-κB signaling, interleukin-2 production, and tumor death in vitro and in vivo .
BibTeX
@inproceedings{zhang2024engineered,
  author = {Wanlu Zhang and Min Wu and Yongye Huang},
  title = {{Engineered CARD11–PIK3R3 T‐cell therapies as weapons of cancer mass destruction}},
  booktitle = {MedComm},
  year = {2024},
  doi = {10.1002/mco2.628},
}
Figure